



Is Early Discontinuation of Antiplatelet Therapy Associated with LaST for Some DES?



¹ Iakovou *et al.*, Incidence, predictors, and outcome of thrombosis after successful implementation of drug-eluting stents, *JAMA* 2005;293:2126–2130

What Are Common Reasons for Antiplatelet Discontinuation?²



Discontinuation of Antiplatelet Therapy

Stent Thrombosis

Compared to bare metal stents
 2–3 times more LaST-related events with CYPHER and TAXUS DES³
 4 times higher risk of cardiac death/MI with LaST³


² Iakovou, Colombo response to Letter to Editor (Marret, Collet, *JAMA*, January 4, 2006; Vol 295, No. 1)

³ Pfisterer *et al.*, Clinical Events Related to Late Stent Thrombosis After Clopidogrel Discontinuation (BASKET-LATE), ACC 2006, TCTMD.org

Remarkable Safety Profile Sustained Over Time

No late stent thrombosis in over 1300 patients

ENDEAVOR I-III Clopidogrel Therapy for ≥ 3 months




NO ANEURYSMAL REMODELING


Only 0.2% late incomplete apposition (1 patient) in ENDEAVOR Combined Results (n = 438 patients)

Endeavor Stent DESigned for Safety

ACUTE SAFETY



> PC biomimetic polymer





> Reduced platelet deposition

LATE SAFETY



> Noninflammatory response and rapid endothelialisation⁴



> Smooth lumen and even neointimal distribution⁵

⁴ Data on file at Medtronic, Inc.

⁵ Representative single stent example ENDEAVOR II (8 mo)